Sign In
Last checked at 
17 May 2010 09:00
ο»Ώ
Β
|
For immediate release |
17 May 2010 |
Β
Β
Β
Futura Medical plc
("Futura" or "the Company")
Β
Director's shareholding
Β
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has received notification from James Barder, the Chief Executive of the Company, that the 100,000 Futura ordinary shares held jointly by his children will no longer be treated as consolidated within his and his wife's holding for the purposes of the AIM Rules as his children are no longer under 18 years of age. As such his aggregate beneficial and non-beneficial holdings will be 745,212 ordinary shares, representing 1.1 per cent of Futura's ordinary share capital.
Β
Β
Β
For any further information please contact:
Β
|
Futura Medical plc |
Β |
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
Β |
Β |
|
mail to: james.barder@futuramedical.com |
www.futuramedical.com |
|
Β |
Β |
|
Nomura Code Securities Limited |
Β |
|
Phil Walker / Giles Balleny |
Tel:+44 (0)20 7776 1200 |
|
Β |
Β |
|
For media enquiries please contact: |
Β |
|
Β |
Β |
|
Buchanan Communications |
Β |
|
Mark Court / Stasa Filiplic / George Prassas |
Tel: +44 (0) 20 7466 5000 |
Β
Β
Notes to Editors
Β
Futura Medical plc
Β
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Β
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
Β
www.futuramedical.com
Β
Β
Β
Follow the stocks
